Read twice and referred to the Committee on Finance.
The bill (SMART Prices Act) amends Medicare drug price negotiation rules in the Social Security Act. It increases the number of drugs subject to negotiation (up to 50 beginning in 2028), shortens the single-source qualification windows to three years, and adjusts statutory percentage caps for the "maximum fair price" across three categories.
Scope and speed of negotiation: liberals favor faster expansion; conservatives oppose expansion.
Relative to its intended legislative type, this bill is a concise, technically specific substantive amendment to the Medicare drug price negotiation statute that clearly defines the statutory changes and an effective date but leaves fiscal, transition, and additional oversight details to existing law or separate processes.
The bill (SMART Prices Act) amends Medicare drug price negotiation rules in the Social Security Act.
It increases the number of drugs subject to negotiation (up to 50 beginning in 2028), shortens the single-source qualification windows to three years, and adjusts statutory percentage caps for the "maximum fair price" across three categories.
The amendments take effect for initial price applicability years beginning 2028.
Technically targeted but politically sensitive; passage depends heavily on legislative vehicle, coalition-building, and counter-lobbying.
Relative to its intended legislative type, this bill is a concise, technically specific substantive amendment to the Medicare drug price negotiation statute that clearly defines the statutory changes and an effective date but leaves fiscal, transition, and additional oversight details to existing law or separate processes.
Scope and speed of negotiation: liberals favor faster expansion; conservatives oppose expansion.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope and speed of negotiation: liberals favor faster expansion; conservatives oppose expansion.
This persona will view the bill positively as a strengthening of the Inflation Reduction Act's drug-price tools to lower costs for Medicare and taxpayers.
They will applaud faster, broader negotiation and tighter qualification windows to bring down prices sooner.
They may still look for stronger consumer protections or broader eligibility, but overall see the bill as progress.
A centrist will view this as a pragmatic, incremental strengthening of existing Medicare negotiation authority.
They will appreciate accelerated implementation and clearer qualification timelines while wanting evidence that savings outweigh potential negative effects on innovation and access.
They will favor measured oversight and cost-benefit analysis.
A mainstream conservative will likely oppose or be skeptical, seeing this as further federal intervention in drug markets.
They will be concerned the changes expand government price control, shorten exclusivity periods, and could reduce incentives for innovation.
They will also worry about litigation, supply effects, and regulatory overreach.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technically targeted but politically sensitive; passage depends heavily on legislative vehicle, coalition-building, and counter-lobbying.
The bill has not accumulated any surfaced votes yet.
Scope and speed of negotiation: liberals favor faster expansion; conservatives oppose expansion.
Technically targeted but politically sensitive; passage depends heavily on legislative vehicle, coalition-building, and counter-lobbying.
Relative to its intended legislative type, this bill is a concise, technically specific substantive amendment to the Medicare drug price negotiation statute that clearly defines the statutory changes and an effective da…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.